- No products in the cart.
Unlike our competitors we ship this product from US DOMESTIC location by usps.com Priority Mail. Delivery time is 3-4 days.
Manufacturer: PureGear Laboratories
Chemical Name: Oxandrolone
Presentation: 40 x 25mg tablet
Active Life: Around 48 hours
Drug Class: Anabolic/Androgenic Steroid
Average Dose: 50-100mg/day
Oxandrolone (Oxandrin) is a drug created by Raphael Pappo while at Searle Laboratories, now Pfizer Inc. under the trademark Anavar, and introduced into the US in 1964.
Oxandrolone is a synthetic anabolic steroid derived from dihydrotestosterone by substituting 2nd carbon atom for oxygen (O). It is widely known for its exceptionally small level of androgenicity accompanied by moderate anabolic effect. Although oxandrolone is a 17-alpha alkylated steroid, its liver toxicity is very small as well. Studies have showed that a daily dose of 20 mg oxandrolone used in the course of 12 weeks had only a negligible impact on the increase of liver enzymes. As a DHT derivative, oxandrolone does not aromatize (convert to estrogen, which causes gynecomastia or male breast tissue). It also does not significantly influence the body’s normal testosterone production (HPTA axis) at low dosages (10 mg). When dosages are high, the human body reacts by reducing the production of LH (luteinizing hormone), thinking endogenous testosterone production is too high; this in turn eliminates further stimulation of Leydig cells in the testicles, causing testicular atrophy (shrinking). Oxandrolone used in a dose of 80 mg/day suppressed endogenous testosterone by 67% after 12 weeks of therapy.
The drug was prescribed to promote muscle regrowth in disorders which cause involuntary weight loss. It had also been shown to be partially successful in treating cases of osteoporosis. However, in part due to bad publicity from its abuses by bodybuilders, production of Anavar was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation, now Savient Pharmaceuticals who, following successful clinical trials in 1995, released it under the tradename Oxandrin. As of 2009, it is the only drug marketed by the company.
It was subsequently approved for orphan drug status by the Food and Drug Administration (FDA) for treating alcoholic hepatitis, Turner syndrome, and HIV-induced weight loss. It is also indicated as an offset to protein catabolism caused by long-term administration of corticosteroids. In addition, the drug has shown positive results in treating anemia and hereditary angioedema. Because of its potential for abuse, it is categorized as a Schedule III controlled substance in the US.
In a randomized, double-blind study, patients with 40% total body surface area burns were selected to receive standard burn care plus oxandrolone, or without oxandrolone. Those treated with oxandrolone showed improved body composition, preserved muscle mass and reduced hospital stay time